Related by context. All words. (Click for frequent words.) 88 primary efficacy endpoint 83 primary endpoints 83 secondary endpoint 80 secondary endpoints 75 primary efficacy endpoints 73 secondary efficacy endpoints 70 non inferiority 70 efficacy endpoints 68 efficacy endpoint 67 secondary efficacy endpoint 67 composite endpoint 65 noninferiority 65 prespecified 64 demonstrated statistically significant 64 statistical significance 64 prospectively defined 64 statistically significant improvement 63 statistically significant reduction 63 Secondary endpoints 63 clinical endpoints 63 achieved statistical significance 63 evaluable patients 63 Secondary endpoints included 62 placebo 61 tolerability 61 clinically meaningful 61 evaluable 61 timepoint 61 mg dose 61 desvenlafaxine succinate 60 placebo controlled 60 free survival PFS 60 p = #.# [002] 60 median PFS 60 achieve statistical significance 59 rolofylline 59 elagolix 59 progression TTP 59 nab paclitaxel 59 undetectable HCV RNA 59 sustained virologic response 59 MEND CABG II 59 plus dexamethasone 59 ACR# response 58 sunitinib 58 chlorambucil 58 glufosfamide 58 tapentadol ER 58 tumor progression TTP 58 bosentan 58 Phase 2b study 58 ACTEMRA 58 mg BID 58 CIMZIA TM 58 monotherapy 58 Secondary endpoints include 57 ACR# [002] 57 ACTEMRA TM 57 oxycodone CR 57 CR nPR 57 active comparator 57 statistically significant 57 virologic response 57 placebo controlled clinical 57 Primary endpoints 57 viral kinetic 57 mcg kg 57 rapid virologic response 57 posaconazole 57 STRIDE PD 57 pharmacodynamic 57 SVR# 57 TRITON TIMI 57 teriflunomide 57 prospective multicenter randomized 57 pharmacokinetics PK 57 virologic failure 57 morphometric vertebral fractures 57 ATACAND 57 vandetanib 57 mg QD 57 LEVADEX 57 randomized double 57 #mg BID [001] 56 reach statistical significance 56 placebo p 56 plus ribavirin 56 REYATAZ r 56 enoximone 56 EURIDIS 56 p = #.# [004] 56 double blind placebo 56 Azixa 56 CIMZIA ™ 56 #mg QD [001] 56 CIMZIA TM certolizumab pegol 56 DSMB 56 placebo p = 56 mg kg dose 56 Kaplan Meier analysis 56 XIENCE V PROMUS Stent 56 randomized controlled 56 mcg BID 56 complete cytogenetic 56 Phase IIb clinical 56 randomized placebo controlled 56 randomized Phase III 56 HbA1c levels 56 TLUS 56 apremilast 56 cytogenetic response 56 Secondary efficacy endpoints 56 Crohn Disease Activity 56 HCV RESPOND 2 56 FOLFOX4 56 surrogate endpoint 56 patients evaluable 56 ABC/3TC 56 rALLy trial 55 #mg/day [001] 55 FOLFIRI 55 neurologic progression 55 prespecified criteria 55 Phase IIa trial 55 docetaxel 55 randomized 55 Solid Tumors criteria 55 p = 55 eplerenone 55 tipranavir 55 Phase IIa clinical 55 reinfarction 55 LEXIVA r 55 mcg QD 55 placebo controlled randomized 55 APPRAISE 55 clinically relevant 55 virological response 55 ribavirin RBV 55 ticagrelor 55 lopinavir r 55 Phase IIa 55 nonfatal MI 55 subanalysis 55 #mg/m# [002] 55 binary restenosis 55 complete cytogenetic response 55 RECIST Response Evaluation Criteria 55 baminercept 55 mg kg 55 pharmacokinetic profile 55 prospective randomized controlled 55 ruboxistaurin 55 analgesic efficacy 55 alvimopan 55 CCyR 55 peginterferon 55 RE LY ® 55 intermittent dosing 55 peginterferon alfa 2a 55 phase IIb clinical 55 nonrandomized 55 retinal thickness 55 viral kinetics 55 Phase Ib clinical 55 tolerated dose MTD 55 teduglutide 54 phase IIa 54 sustained virological response 54 EVEREST II 54 pain palliation 54 pegylated interferon 54 clinically meaningful improvement 54 disease progression 54 XGEVA 54 plus gemcitabine 54 HbA1c 54 Phase 1b 54 unblinded 54 KRN# 54 target vessel revascularization 54 recurrent GBM 54 Phase 2a trial 54 PASI scores 54 dosing regimens 54 Lupuzor ™ 54 aflibercept 54 dosage regimens 54 P = .# 54 ALVESCO 54 IIIa inhibitor 54 GOUT 54 post hoc 54 Phase 2b clinical 54 dose escalation 54 Thrombolysis 54 timepoints 54 endoscopic remission 54 iclaprim 54 FOLFOX 54 plus methotrexate 54 mucosal healing 54 everolimus eluting stents 54 Index CDAI 54 lopinavir r arm 54 azacitidine 54 clinically meaningful improvements 54 angiographic outcomes 54 SPIRIT FIRST 54 CDAI 54 BENICAR HCT 54 virologic 54 fondaparinux 54 randomized Phase 2b 54 tanespimycin 54 carboplatin paclitaxel 54 dose limiting toxicities 54 #.#/#.# mmHg [001] 54 cangrelor 54 Scale EDSS 54 #mg BID [003] 54 efficacy 54 CHAMPION PLATFORM 54 Phase 2b trial 54 pharmacokinetic 54 serum phosphorus 54 adalimumab 54 peginterferon alfa 2b 54 nonresponders 54 ACE inhibitor ramipril 54 lymphoma CTCL 54 picoplatin 54 tolvaptan 54 Phase 2a clinical 54 MEND CABG 54 recurrent glioblastoma multiforme 54 mITT population 54 sUA 54 bicifadine 54 oral rivaroxaban 54 PROMACTA 54 TMC# C# 53 TACE 53 TIMI 53 spontaneous bowel movements 53 remission CR 53 #mg QD [002] 53 FOLPI 53 Amrubicin 53 Fludara 53 Free Survival PFS 53 phase IIIb 53 TAXUS Stent 53 mapatumumab 53 mg/m2 dose 53 HCV RNA 53 NLX P# 53 XIENCE V demonstrated 53 vismodegib 53 Montgomery Asberg Depression 53 sirolimus eluting stent 53 Response Evaluation Criteria 53 levosimendan 53 gout flares 53 pharmacodynamic effects 53 PREZISTA r 53 achieved ACR# 53 Target Lesion Revascularization TLR 53 mcg dose 53 oral ridaforolimus 53 randomized multicenter 53 dose escalation study 53 dose cohorts 53 iniparib 53 limiting toxicity 53 tolerability profile 53 tiotropium 53 Adalimumab 53 octreotide LAR 53 mRCC 53 elotuzumab 53 varespladib 53 BRIM2 53 Phase III clinical 53 cardiovascular morbidity 53 peg interferon 53 biologic therapy 53 DAPT 53 edoxaban 53 mcg albinterferon alfa 2b 53 clazosentan 53 CSBM 53 PEG Intron 53 Corlux 53 lintuzumab 53 clodronate 53 NEVO ™ 53 tecarfarin 53 Rating Scale MADRS 53 pegylated interferon alfa 2b 53 telaprevir dosed 53 ipsilateral stroke 53 Phase 2b 53 MACCE 53 n = 53 Expanded Disability Status 53 administered subcutaneously 53 LPV r 53 multicentre randomized 53 EFAPROXYN 53 imatinib therapy 53 safety tolerability 53 Kaplan Meier estimate 53 Median PFS 53 MADRS score 53 HBeAg seroconversion 53 ibandronate 53 BENICAR 53 placebo controlled Phase 53 prospective randomized 53 infliximab 53 ischemic cardiomyopathy 53 plus prednisone 53 annualized relapse 53 symptomatic VTE 53 dosing regimen 53 rotigotine 53 decitabine 53 pertuzumab 53 bortezomib 53 Zerenex 53 dimebon 53 achieve sustained virologic 53 pegylated interferon peg IFN 53 adjuvant GIST 53 PRIMO CABG2 53 vidofludimus 53 randomization 53 diameter stenosis 53 COMFORT II 53 irbesartan 53 tipranavir r 53 ADX# 53 multiple ascending dose 53 Fibrin Pad 53 5-FU/LV 53 Psoriasis Area 53 imatinib 53 achieved PASI 53 HCV SPRINT 53 eptifibatide 53 pharmacokinetics 53 Major Adverse Cardiac 53 RECIST criteria 53 Board DSMB 53 undetectable HBV DNA 53 antipsychotic efficacy 53 PRECiSE 52 oral diclofenac 52 double blinded placebo 52 adjunctive placebo 52 endpoints 52 viral load 52 comparator arm 52 Randomized Evaluation 52 VELCADE melphalan 52 romiplostim 52 doxorubicin docetaxel 52 placebo controlled clinical trials 52 cabazitaxel 52 detectable HCV RNA 52 headache nasopharyngitis 52 NYHA functional class 52 refractory NSCLC 52 MAP# 52 midstage study 52 MADRS 52 biochemical recurrence 52 eculizumab 52 sumatriptan naproxen sodium 52 sorafenib 52 FDA defined valvulopathy 52 insulin detemir 52 inflammatory lesions 52 ancrod 52 statistically significant p = 52 pivotal Phase III 52 dexpramipexole 52 DAS# remission 52 phase Ib 52 pharmacokinetic PK 52 severe exacerbations 52 RoACTEMRA 52 brivaracetam 52 CYPHER ® Stent 52 NYHA Class II 52 4mg/kg 52 pharmacokinetic PK profile 52 relapsing multiple sclerosis 52 dosing 52 intravenous dosing 52 μg dose 52 Phase III pivotal 52 maximally tolerated dose 52 Median progression 52 thromboembolic events 52 atazanavir ritonavir 52 melphalan prednisone 52 SIMPADICO 52 pharmacodynamic PD 52 randomized controlled clinical 52 ULORIC 52 candesartan cilexetil 52 Virulizin ® 52 virologic response EVR 52 infarct size 52 HBeAg positive patients 52 paclitaxel carboplatin 52 MIST II 52 Phase Ib 52 docetaxel chemotherapy 52 diabetic neuropathic pain 52 primary hypercholesterolemia 52 EDEMA3 52 blind randomized placebo 52 valopicitabine 52 death reinfarction 52 rivaroxaban 52 bevacizumab 52 TAXUS 52 Onrigin 52 Pegasys ® 52 pivotal Phase 52 EDEMA4 trial 52 multicenter randomized double 52 PEG Interferon lambda 52 Phase III placebo controlled 52 NATRECOR ® 52 null responder HCV 52 adefovir 52 Cmax 52 TAXUS Express Stent 52 prespecified secondary 52 CR CRu 52 serum phosphorous 52 prospective multicenter 52 prospective randomized multicenter 52 randomized clinical 52 statistical significance p 52 Phase IIIb 52 ataluren 52 CALGB # [001] 52 Recentin 52 plus COPEGUS 52 pexelizumab 52 Phase IIIb clinical 52 CDAI score 52 dosing cohorts 52 lumbar spine BMD 52 multicenter Phase 52 Sustained Virological Response 52 blinatumomab 52 APTIVUS r 52 cardiovascular hospitalization 52 icatibant 52 phase IIb 52 multicenter randomized placebo controlled 52 Ereska 52 axitinib 52 Phase 2a 52 CLARITY study 52 mITT 52 AVADO 52 HBeAg negative patients 52 dose escalation phase 52 docetaxel Taxotere ® 52 phase IIa clinical 52 TAXUS ATLAS 52 DAS# [002] 52 subcutaneously administered 52 EGFR TKI 52 dacetuzumab 52 octreotide 52 Sustained virologic response 52 randomized blinded 52 demonstrated clinically meaningful 52 blind placebo controlled 52 dose regimens 52 daclizumab 52 Tarceva TM 52 chronic angina 52 rosuvastatin #mg 52 Phase IIb 52 RG# [001] 52 SinuNase 52 APEX AMI trial 52 HIV RNA 52 MoxDuo TM IR 52 oral FTY# 52 velafermin 52 peg IFN 52 mitoxantrone 52 log# reduction 52 NATRECOR R 52 blind randomized 52 Androxal TM 52 Acute Ischemic Stroke 52 T#I [002] 52 ENDEAVOR IV 52 pCR 52 PFO migraine 51 multicenter 51 randomized multicenter trial 51 refractory AML 51 abatacept 51 HAQ DI 51 subgroup analyzes 51 ARIXTRA 51 IFN alfa 51 pramlintide 51 SIMPADICO trial 51 #mg BID [002] 51 atheroma volume 51 QNEXA 51 ILLUMINATE 51 AEGR 51 seroconversion 51 radiographic progression 51 plasma concentrations 51 response CCyR 51 low dose cytarabine 51 copies mL 51 certolizumab 51 GAMMAGARD 51 PEGylated interferon beta 1a 51 degarelix 51 HAMD 51 aliskiren 51 candesartan 51 posttreatment 51 motavizumab 51 beclomethasone dipropionate 51 colesevelam HCl 51 cethromycin 51 pharmacokinetic equivalence 51 ongoing Phase 1b 51 Zenvia 51 Bronchitol 51 FOLOTYN 51 celgosivir 51 Dacogen injection 51 dacarbazine 51 specified primary endpoint 51 PROTECT II 51 endpoint 51 ACR# ACR# 51 CANCIDAS 51 RE LY trial 51 creatinine clearance 51 estramustine 51 AGILECT R 51 #mg dose [003] 51 SYMMETRY trial 51 riociguat 51 nilotinib 51 clinical trial 51 safety tolerability pharmacokinetics 51 PRECISE 51 ascending doses 51 segment binary restenosis 51 sirolimus eluting stents 51 CTEPH 51 milatuzumab 51 multicenter randomized 51 trough FEV1 51 gefitinib 51 zonisamide SR 51 abacavir lamivudine 51 randomized discontinuation trial 51 BARACLUDE r 51 multicentre 51 CARE HF 51 rindopepimut 51 fosbretabulin 51 BRIM3 51 Doxil ® 51 gemcitabine 51 Pegasys plus Copegus 51 randomized #:# 51 phase IIb study 51 dose escalation trial 51 Octreolin 51 ADAGIO study 51 tocilizumab 51 VIRAMUNE XR 51 denufosol 51 REMINYL ® 51 DASISION 51 EOquin 51 cell lymphoma CTCL 51 Cimzia TM 51 interferon ribavirin 51 Phase 1b clinical 51 plasma HCV RNA 51 methylnaltrexone 51 belimumab 51 Telcyta 51 Sorafenib HCC Assessment 51 oral methylnaltrexone 51 Maximum Tolerated Dose 51 FOSRENOL ® 51 mCRC patients 51 Solid Tumours 51 temsirolimus 51 Traficet EN 51 Phase IIb trial 51 serologically active patients 51 splenectomized patients 51 glycated hemoglobin levels 51 QTcF 51 noninferior 51 attain statistical significance 51 phase 2a 51 blinded randomized 51 urinary N telopeptide 51 lumiliximab 51 8mg/kg 51 budesonide 51 STELARA 51 imetelstat 51 insulin glargine 51 salmeterol fluticasone 51 definite stent thrombosis 51 Amigal 51 COPEGUS 51 ZOLINZA 51 ximelagatran 51 INC# 51 invasive aspergillosis 51 liver histology 51 DMARD 51 LIALDA 51 Ceplene/IL-2 51 etanercept 51 serum HCV RNA 51 multicenter randomized controlled 51 abiraterone acetate 51 ABSORB trial 51 alicaforsen enema 51 bortezomib refractory 51 liver metastases 51 Ocrelizumab 51 dosing cohort 51 PREZISTA r arm 51 nonsignificant 51 label multicenter 51 log# 51 oblimersen 51 #mg/kg [002] 51 pharmacodynamics PD 51 MYDICAR 51 tirofiban 51 OMNARIS HFA 51 null responders 51 interferon gamma 1b 51 ACR# responses 51 fluoropyrimidine 51 GSK# [001] 51 prospective randomized placebo 51 IR prednisone 51 crizotinib PF # 51 TAXUS IV 51 HDRS 51 systolic BP 51 statistically significant superiority 51 bosutinib 51 LVEF 51 relapsed refractory multiple myeloma 51 chemoradiation 51 double blinded randomized 51 Hb A1C 51 unblinding 51 Neuropsychiatric Inventory NPI 51 placebo controlled dose escalation 51 IPSS 51 SYNTAX trial 51 RECIST 51 ENDEAVOR II 51 lanthanum carbonate 51 dose titration 51 #mg/m# [001] 51 ADAS cog 51 ToGA 51 topotecan 51 aprepitant 51 serum urate 51 IRESSA 51 erlotinib 51 ARCOXIA 51 zotarolimus eluting stent 51 zalutumumab 50 PEGylated anti 50 custirsen 50 pharmacokinetic parameters 50 mycophenolate mofetil 50 antiplatelet agent 50 COMBIVIR 50 investigational compound 50 Phase III randomized 50 sitaxsentan 50 Dextofisopam 50 ADVANCE PD 50 statistically significant differences 50 tumor shrinkage 50 ANCHOR trial 50 TAXUS Liberte Long 50 INCB# [002] 50 chemoradiotherapy 50 INCB# [001] 50 efficacy tolerability 50 1mg dose 50 LEXIVA 50 LymphoStat B 50 Tiotropium 50 ZOMIG Nasal Spray 50 solifenacin 50 pegylated liposomal doxorubicin 50 RGT arm 50 CRp 50 SCH # 50 eszopiclone 50 TELCYTA 50 RAPAFLO R 50 Prochymal 50 predefined criteria 50 SPIRIVA HandiHaler 50 mg ustekinumab 50 Aptivus ® 50 R# #mg BID 50 locoregional disease 50 evaluable subjects 50 Solid Tumors RECIST 50 Events MACE 50 ocrelizumab 50 Unified Parkinson Disease 50 peginterferon alfa 2a #KD 50 trospium 50 seropositive patients 50 Xinlay 50 sorafenib Nexavar 50 coadministration 50 Betaferon ® 50 ritonavir boosted 50 Phase #b/#a clinical 50 single ascending dose 50 recurrent ischemia 50 ascending dose 50 MitraClip device 50 CombAT 50 SPIRIT III 50 CoreValve System 50 regorafenib 50 receiving golimumab 50 antiviral efficacy 50 follicular NHL 50 CLL8 50 SABCS 50 peginesatide 50 TroVax 50 PRE SURGE 50 mg TID 50 ACCORD Lipid 50 AeroLEF 50 neoadjuvant chemotherapy 50 Cloretazine 50 HCV genotype 1 50 ZYBRESTAT 50 NYHA Class III 50 PIX# [002] 50 allopurinol 50 disease progression TTP 50 trials RCTs 50 lixisenatide 50 CI -#.# 50 Darusentan 50 cilostazol 50 CRESTOR #mg 50 Rivaroxaban 50 dacarbazine chemotherapy 50 mg doses 50 oral prodrug 50 esomeprazole 50 Phase III HEAT 50 ≥ 50 Elitek 50 NSABP C 50 interferon alfa 50 dose regimen 50 remission induction 50 pharmacokinetic PK study 50 certolizumab pegol 50 serum testosterone 50 TAXUS VI 50 PSADT 50 bone metastases 50 valsartan 50 SPIRIT IV 50 univariate analysis 50 chemoradiation therapy 50 FOLFOX6 50 NEVO 50 log# IU mL 50 baseline HbA1c 50 APTIVUS 50 Taxotere ® 50 RSD# oral 50 pramlintide metreleptin combination 50 FEV1 50 L PPDS 50 COPAXONE R 50 plasma uric acid 50 angiographic restenosis 50 EDSS score 50 NV1FGF 50 panitumumab 50 nausea photophobia 50 pharmacodynamics 50 Phase III 50 YERVOY 50 undetectable viral load 50 Patency 50 mg d 50 Phase IIB 50 Solid Tumors 50 abdominal pain abdominal discomfort 50 febrile neutropenia 50 selective modulator 50 vicriviroc 50 Phase 1b trial 50 alteplase 50 TNF inhibitor 50 lispro 50 events AEs 50 relapsed refractory 50 Endarterectomy 50 TAXUS p value 50 dabigatran etexilate 50 % CI #.#-#.# [003] 50 evaluating REVLIMID 50 randomized Phase IIb 50 dyskinesia PD LID 50 biochemical relapse 50 NYHA class 50 Carotid Revascularization Endarterectomy vs. 50 multicenter Phase II 50 lubiprostone 50 μg kg 50 genotypic resistance 50 SBMs 50 multicenter placebo controlled 50 QD dosing 50 iloprost 50 catheter occlusion 50 ug kg 50 methotrexate MTX 50 ustekinumab 50 Phase Ib study 50 Folfox 50 KRAS mutations occur 50 Campath alemtuzumab 50 darusentan 50 huC# DM4 50 oral Xeloda 50 TORISEL 50 pomalidomide 50 Sprycel dasatinib 50 orBec 50 gadolinium enhancing lesions 50 Hedgehog Pathway Inhibitor 50 trastuzumab 50 heavily pretreated 50 TAXUS stent 50 anti leukemic 50 dosing intervals 50 relapsed CLL 50 cystectomy 50 AVOREN 50 Rezular 50 p = NS 50 locoregional recurrence 50 nasal symptom 50 #μg [002] 50 clinically evaluable population 50 vinorelbine 50 opioid induced bowel dysfunction 50 Phase Ia 50 Aflibercept 50 DAS# CRP 50 dose escalation clinical 50 Xcytrin 50 everolimus 50 zoledronic acid 50 DSM IV criteria 50 Flu Cy 50 CK # 50 nodular partial response 50 eltrombopag 50 relapsed MCL 50 ELND# 50 intravascular hemolysis 50 Median survival 50 dirucotide 50 ELACYT 50 Phenoptin 50 treatment emergent adverse 50 RRMS patients 50 cediranib 50 Ranolazine 50 serum uric acid sUA 50 PEGPH# 50 Phase Ib II 50 ExTRACT TIMI 50 Ostarine 50 Primary Endpoint 50 cardiovascular hospitalizations 50 confirmatory clinical 50 HORIZONS AMI trial 50 reslizumab 50 pemetrexed 50 proteinuria 50 Forodesine HCl 50 relapsed myeloma 50 Itopride 50 metastatic castration resistant 50 Vectibix 50 acute coronary syndromes ACS 50 HGS ETR2 50 MERLIN TIMI 50 abciximab 49 HGS ETR1 49 hormone refractory prostate cancer 49 PRIMO CABG 49 dexamethasone 49 EMPHASIS HF trial 49 ofatumumab 49 alpha 2a 49 q#h 49 Welchol 49 League Against Rheumatism 49 satraplatin Phase 49 PEG IFN 49 recurrent malignant glioma 49 rilpivirine 49 telbivudine 49 Endpoints 49 Efficacy Results 49 Lucentis monotherapy 49 OPAXIO 49 ASTEROID 49 renal function 49 HbA 1c 49 stage IIIB 49 Phase 1a 49 ONTARGET 49 XELOX 49 NOXAFIL 49 Laquinimod 49 FTY# 49 olmesartan 49 INCB# [003] 49 serum phosphate levels 49 goserelin 49 EVIZON 49 graft dysfunction 49 pulmonary exacerbations 49 pharmacokinetic characteristics 49 adjuvant colon cancer 49 metastatic hormone refractory 49 mg/m2 49 placebo controlled Phase III 49 Val HeFT 49 microbiological eradication 49 sirolimus 49 Tolvaptan 49 RESIST studies 49 Monotherapy 49 periprocedural 49 plasma pharmacokinetics 49 phase IIb trial 49 vernakalant 49 atrasentan 49 oral allopurinol 49 recurrent VTE 49 antitumor activity 49 Pharmacokinetic 49 VAPRISOL 49 relapsed GBM 49 Xalatan R 49 EBMT criteria